Shares of Sequenom, Inc. (NASDAQ:SQNM) closed at $2.39 with 501,301.00 shares getting traded. Post opening the session at $2.39, the shares hit an intraday low of $2.39 and an intraday high of $2.40 and the price vacillated in this range throughout the day. The company has a market cap of $285.59 million and the numbers of outstanding shares have been calculated to be 119.24 million shares.
Sequenom, Inc. (SQNM) develops and commercializes molecular diagnostics testing services for the women’s health and oncology markets in the United States and internationally. The company provides molecular based laboratory developed tests (LDTs) comprising MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; and VisibiliT LDT, a NIPT to detect fetal chromosomal abnormalities by determining the relative amount of chromosomal material present in circulating cell-free DNA in a maternal blood sample.
Shares of Idera Pharmaceuticals Inc (NASDAQ:IDRA) ended Tuesday session in red amid volatile trading. The shares closed down -0.01 points or -0.51% at $1.94 with 158,814.00 shares getting traded. Post opening the session at $1.96, the shares hit an intraday low of $1.94 and an intraday high of $1.98 and the price vacillated in this range throughout the day. The company has a market cap of $240.41 million and the numbers of outstanding shares have been calculated to be 121.38 million shares.
Idera Pharmaceuticals Inc (IDRA) on Aug. 02, 2016 reported its financial and operational results for the second quarter ended June 30, 2016.
“The second quarter of this year represented a period of solid execution throughout the organization,” stated Vincent Milano, Idera’s Chief Executive Officer. “As a result of the efforts of the team to continue driving our programs forward, we are rapidly approaching critical data readouts for Idera. During the second half of this year, we expect to be in position to share important data from our melanoma trial with IMO-2125, as well as the next steps in the program. We also expect to be in a position to select a recommended Phase 2 dose for our B-cell lymphoma program with IMO-8400. Lastly, we plan to begin elucidating the path forward for the 3GA (third generation antisense) platform, which we believe represents a pillar in the foundation of the company we are building.”
Continued Milano, “I’m very proud of the team’s focus and determination as they continued to advance our research and development programs. We certainly have much more work ahead of us to arrive at our ultimate goal of delivering solutions to patients; however, we are energized knowing that we will soon be in possession of critical information to further understand the potential of these opportunities.”
Research and Development Program Updates
IMO-2125 and IMO-8400 are the Company’s lead clinical development drug candidates. IMO-2125 is an oligonucleotide-based agonist of Toll-like receptor (TLR) 9. IMO-8400 is an oligonucleotide-based antagonist of TLRs 7, 8, and 9. The Company also announced during the fourth quarter of 2015, the first two development targets from its proprietary 3GA Technology platform: NLRP3 (NOD-like receptor family, pyrin domain containing protein 3) and DUX4 (Double Homeobox 4). The Company continues to evaluate these and other potential targets for clinical proof of concept. The Company plans to take the first 3GA candidate into human proof of concept studies in 2017.